Clinical Outcome of Bortezomib Retreatment in Patients with Relapsed or Refractory Multiple Myeloma


This retrospective study investigated the clinical efficacy and safety of bortezomib retreatment in patients with relapsed or refractory multiple myeloma (MM). A total of 30 patients who relapsed or progressed after ≥6 months since the last dose of their previous bortezomib therapy were included in this study. During the median 6 cycles (range: 2-12) of… (More)
DOI: 10.1155/2014/145843

5 Figures and Tables


  • Presentations referencing similar topics